Physician profile
Kevin Moore
NPI 1164927042
$1,697.65
in general payments reported to CMS, 2019-2025
18 companies · $956 in 2025
The $956 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.33 · 2024: $711 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.45 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $227.90 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $143.89 | 2024-2025 | |
| Janssen Biotech, INC. | $142.97 | 2024-2025 | Simponi, Simponi Aria, Stelara |
| Incyte Corporation | $133.16 | 2024 | Opzelura |
| Leo Pharma INC. | $125.09 | 2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $99.22 | 2024-2025 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $65.88 | 2025 | |
| Sun Pharmaceutical Industries INC. | $47.17 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $43.25 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $42.75 | 2024-2025 | Taltz, Ebglyss |
| Ucb, INC. | $35.81 | 2025 | Bimzelx |
| Organon LLC | $31.39 | 2025 | |
| Glaxosmithkline, LLC. | $31.33 | 2021 | |
| Verrica Pharmaceuticals INC. | $27.19 | 2024 | Ycanth |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.51 | 2025 | Spevigo |
| Biofrontera INC. | $20.50 | 2025 | |
| Amgen INC. | $18.19 | 2024 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.